CHAN 340B Brochure

For many healthcare organizations, the 340B Drug Pricing Program offers significant cost savings that enables them to continue serving at-risk populations. However, the lack of clarity within the program’s complex regulations and increased scrutiny over covered entity operations has made it challenging for many healthcare entities to remain compliant while also meeting the U.S. Health Resources and Services Administration’s (HRSA’s) expectations.